|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 51/00 | |
| A61K 39/42 | |||
| A61K 39/40 | |||
| A61K 47/18 | |||
| A61K 47/42 |
| (11) | Number of the document | 2656859 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13173674.6 |
| Date of filing the European patent application | 2005-03-03 | |
| (97) | Date of publication of the European application | 2013-10-30 |
| (45) | Date of publication and mention of the grant of the patent | 2015-10-21 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 550015 P | 2004-03-03 | US |
| (72) |
Dake, Michael D., US
Waugh, Jacob M., US
|
| (73) |
ReVance Therapeutics, Inc.,
7555 Gateway Blvd., Newark, CA 94560,
US
|
| (54) | Topical application and transdermal delivery of botulinum toxins |
| Topical application and transdermal delivery of botulinum toxins |